Puyuan Xing

机构：Chinese Academy of Medical Sciences & Peking Union Medical College · ORCID：0000-0003-4415-9892

发表论文 280 篇 · 总被引 3063 次 · h-index 30

代表论文

• Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial (2025 · Nature Medicine · 被引 30)
• Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas (2024 · Signal Transduction and Targeted Therapy · 被引 24)
• Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review) (2024 · Oncology Letters · 被引 15)
• A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma (2025 · Experimental Hematology and Oncology · 被引 12)
• Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs (2024 · Journal of Translational Medicine · 被引 7)
• RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations (2025 · Cell Reports Medicine · 被引 6)